Sorbact® is a registered trademark owned by
Sorbact
Safe and effective removal of bacteria reduces the bioburden in wounds which facilitates the healing process. It is also shown that Sorbact® exhibits high cell compatibility and does not change cell morphology. Moreover there is a minimized cell attachment to the dressing surface which thereby increases safety towards tissues.
No contraindications and low risk of allergies
Reduces the bioburden in wounds1, 2
Immediate onset of action3
Development of bacterial resistance is not expected
No release of active agents into the wound4
Suitable for prolonged treatment
Does not promote the bacterial release of endotoxins5
Common wound microorganisms, such as Staphylococcus aureus, Streptococcus species, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, bind to the unique surface of Sorbact®.* Sorbact® also binds MRSA (methicillin-resistant Staphylococcus aureus)6, VRE (Vancomycin-resistant Enterococcus) and targets fungi.
*In vitro data
With the Sorbact® mode of action, unlike certain antimicrobial substances that kill microbes, development of bacterial or fungal resistance is not expected, and it can be used for a prolonged period of time.
Elevated microbe levels will result in risk of infection and delayed wound healing. Sorbact® safely reduces the bioburden thus improving the conditions for efficient wound healing.
Sorbact® can be used to prevent and treat wound infections and in conjunction with systemic antibiotic therapy if needed.
